An observational study suggests that administration of phosphorus binders dramatically improves survival rates in patients on incident hemodialysis—even in those without hyperphosphatemia. Randomized clinical trials should drive changes in the relevant clinical practice.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
K/DOQI workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am. J. Kidney Dis. 45 (4 Suppl. 3), S1–S153 (2005).
Isakova, T. et al. Phosphorus binders and survival on hemodialysis. J. Am. Soc. Nephrol. 20, 388–396 (2009).
Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324, 71–86 (2002).
Freemantle, N., Cleland, J., Young, P., Mason, J. & Harrison, J. β-Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 318, 1730–1737 (1999).
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 39 (2 Suppl. 1), S1–S266 (2002).
Besarab, A. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 339, 584–590 (1998).
Eknoyan, G. et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N. Engl. J. Med. 347, 2010–2019 (2002).
Wanner, C. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353, 238–248 (2005).
Fellstrom, B. C. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360, 1395–1407 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
G. M. Chertow declares associations with the following companies: Amgen, as consultant and recipient of grant/research support, and Genzyme Corporation, as consultant. J. H. Ix declares no competing interests.
Rights and permissions
About this article
Cite this article
Ix, J., Chertow, G. Phosphorus binders and survival: need for randomized trials. Nat Rev Nephrol 5, 368–370 (2009). https://doi.org/10.1038/nrneph.2009.78
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2009.78
